|
1）臼杵憲祐．再生不良性貧血の重症度別治療方針．臨床血液．2012; 53(10): 1500-8
|
|
|
|
2）Metcalf D. A promising new treatment for refractory aplastic anemia. N Engl J Med. 2012; 367(1): 74-5
|
|
|
|
|
3）Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1): 11-9
|
|
|
|
|
|
4）Ballmaier M, Germeshausen M. Advances in the understanding of congenital amegakaryocytic thrombocytopenia. Br J Haematol. 2009; 146: 3-16
|
|
|
|
|
|
5）Desmond R. Townsley D, Olnes M, et al. Is possible to cure severe aplastic anemia refractory to immunosuppressive therapy without transplant? A long term follow up analysis of a phase II study ot eltrombopag. Haematologica. 2013; 98(S1); 454a
|
|
|
|
|
|
6）Usuki K, Tahara T, Iki S, et al. Serum thrombopoietin level in various hematological diseases. Stem Cells. 1996; 14: 558-65
|
|
|
|
|
|
7）Walne AJ, Dokal A, Plagnol V, et al. Exome sequencing identifies MPL as a causative gene in familial aplastic anemia. Haematologica. 2012; 97(4): 524-8
|
|
|
|
|
|
8）Oshim Y, Yuj K, Tanimoto T, et al. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. Inern Med. in press (Blood 2012; 120: 3541a)
|
|
|
|
|
|
9）Giagounidis A, Mufti GJ, Kantarjian HM, et al. Treatment with the thrombopoietin-receptor ag-onist romiplostim in thrombocytopenic patients with low or intermediate-1 risk myelodysplastic syndrome: results of a randomized, double-blind, placebo-controlled study. Blood. 2011; 118: 117a
|
|
|
|
|
|
10）Kantarjian HM, Ghulam J, Mufti GJ, et al. Treatment with the thrombopoietin-receptor agonist romiplostim in thrombocytopenic patients with low or intermediate-1 risk myelodysplastic syndrome: follow-up AML and survival results of a randomized, double-blind, placebo-controlled study. Blood. 2012; 120: 421a
|
|
|
|
|
|
11）Sekeres MA, Giagounidis A, Kantarjian HM, et al. Development and validation of a model to predict response to romiplostim in patients with lower-risk myelodysplastic syndromes. Blood. 2012; 120: 2801a
|
|
|
|
|
|
12）Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009; 114: 3899-908
|
|
|
|
|
|
13）Erickson-Millera CL, Kirchnera J, Aivado M, et al. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leukemia Research. 2010; 34: 1224-31
|
|
|
|
|
|
14）Rusnak DW, Rudolph SK, Safavi A, et al. Eltrombopag, but not romiplostim or thrombopoietin, inhibits growth of thrombopoietin receptor positive and negative human leukemia cell lines. Blood. 2012; 120: 4726a
|
|
|
|
|
|
15）Oliva EN, Santini V, Zini G, et al. Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS). Blood. 2012; 120: 923a
|
|
|
|
|
|
16）Mittelman M, Assouline S, Briasoulis E, et al. Eltrombopag treatment of thrombocytopenia in advanced myelodysplastic syndromes and acute myeloid leukemia: results of the 8-week open-label part of an ongoing study. Blood. 2012; 120: 3822a
|
|
|
|
|
|
17）Frey NV, Hexner EO, Porter DL, et al. A phase I clinical trial using eltrombopag in patients with acute myelogenous leukemia. Blood. 2012; 120: 3576a
|
|
|
|
|